Advyzon Investment Management LLC Invests $282,000 in CRISPR Therapeutics AG $CRSP

Advyzon Investment Management LLC bought a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 5,792 shares of the company’s stock, valued at approximately $282,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CRSP. SVB Wealth LLC acquired a new position in shares of CRISPR Therapeutics during the 1st quarter worth about $25,000. Costello Asset Management INC acquired a new stake in shares of CRISPR Therapeutics in the first quarter valued at about $27,000. Atlantic Union Bankshares Corp bought a new stake in CRISPR Therapeutics during the second quarter worth about $33,000. Quantbot Technologies LP boosted its position in CRISPR Therapeutics by 272.4% during the first quarter. Quantbot Technologies LP now owns 1,337 shares of the company’s stock valued at $45,000 after purchasing an additional 978 shares during the last quarter. Finally, IFP Advisors Inc grew its stake in CRISPR Therapeutics by 24.6% in the second quarter. IFP Advisors Inc now owns 916 shares of the company’s stock valued at $45,000 after purchasing an additional 181 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Stock Performance

Shares of CRSP opened at $52.19 on Thursday. The firm has a market cap of $4.97 billion, a P/E ratio of -9.34 and a beta of 1.89. CRISPR Therapeutics AG has a 52 week low of $30.04 and a 52 week high of $78.48. The firm’s 50-day simple moving average is $63.02 and its 200 day simple moving average is $53.44.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, November 10th. The company reported ($1.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.32) by $0.15. The firm had revenue of $0.89 million during the quarter, compared to the consensus estimate of $8.74 million. CRISPR Therapeutics had a negative net margin of 1,273.70% and a negative return on equity of 21.23%. As a group, equities analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Wall Street Analyst Weigh In

CRSP has been the topic of a number of analyst reports. Chardan Capital reiterated a “buy” rating and set a $82.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, August 5th. Robert W. Baird lowered their target price on shares of CRISPR Therapeutics from $52.00 to $44.00 and set a “neutral” rating on the stock in a report on Tuesday. Wedbush dropped their price target on shares of CRISPR Therapeutics from $13.00 to $9.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 5th. Bank of America lifted their price objective on shares of CRISPR Therapeutics from $78.00 to $93.00 and gave the company a “buy” rating in a research report on Friday, October 17th. Finally, Royal Bank Of Canada boosted their price objective on shares of CRISPR Therapeutics from $42.00 to $50.00 and gave the stock a “sector perform” rating in a research note on Tuesday. Eleven analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $67.84.

Insider Buying and Selling at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 50,895 shares of the company’s stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $67.91, for a total value of $3,456,279.45. Following the transaction, the chief executive officer directly owned 254,201 shares in the company, valued at approximately $17,262,789.91. This represents a 16.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel James R. Kasinger sold 1,076 shares of the firm’s stock in a transaction dated Tuesday, October 14th. The stock was sold at an average price of $66.60, for a total transaction of $71,661.60. Following the transaction, the general counsel directly owned 83,402 shares in the company, valued at approximately $5,554,573.20. This represents a 1.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 56,213 shares of company stock worth $3,810,458 in the last quarter. Company insiders own 4.30% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.